

Index

- absorption 335–36, 347–50
- absorptive capacity 175
- ADME parameters 335, 342
- administrative controls 360–61, 364–68, 371
- AFM *see* atomic force microscope
- agglomeration 81, 144–45, 155, 157, 161, 169, 347
- agglomeration state 334, 341, 354
- agriculture sector 59–61, 283
- airborne particles, release of 364–65
- ALARP *see* As Low As Reasonably Practicable
- allergy 344–45
- aluminium oxide 354
- alveolar clearance 346
- American Society for Testing and Materials (ASTM) 291, 324
- anatase 343, 347–48, 362
- antimicrobial activity 351
- antioxidants 24, 50, 348
- apoptosis 342
- application and market advisory board 183
- applications
 - biomedical 12, 30, 51, 66–67, 348, 351
 - commercial 24, 181
 - end-user 385–86
 - nanoparticle technology 44
 - nanotechnology 331
 - personal care 24, 49
- applied nanotechnology 254–55, 257
- arena 202
- Arnstein's ladder 428–29
- arsenic 353
- artefacts 308–9, 311
- As Low As Reasonably Practicable (ALARP) 355, 373
- ASTM *see* American Society for Testing and Materials
- atomic force microscope (AFM) 290, 295–96, 298, 311–14, 322, 324
- atomic force microscopy 311
- attrition milling 359
- autoclaves 98, 100, 102
- autoimmune 345
- automotive applications 209–10
- bandgap energy 20, 22, 150, 158
- base market 180–81, 184–85
- batteries 46, 55, 213, 215, 229
- beachhead application 176, 181, 184–88, 190, 193, 200, 228
- benchmark exposure levels 355, 370
- benign-by-design approach 332
- benzyl alcohol 89–91
- BET *see* Brunauer–Emmett–Teller
- BET particle size 154, 161–62
- bioactivity 332, 341
- bioavailability 334, 370
- biocompatibility 351–52, 363–64
- biodegradable 344, 353
- biodistribution 340, 363
- biohazard cabinets 365
- bioindicators 346

- biological effects 332–34, 341–42, 372
- biomarkers of exposure/effect 360
- biomedical nanotechnology 70–71
- biomonitoring 345
- biotechnology product
development 194
- biotransformation 342
- bottom-up production 359
- British Standards Institution (BSI) 291, 324
- Brunauer–Emmett–Teller (BET) 154, 161, 163, 297, 324
- BSI *see* British Standards Institution
- bulk materials 6, 8, 15, 22, 28, 31, 75, 143, 332, 334, 359, 370, 372
- cadmium 353
- calibration 288–89, 297, 299, 309, 311, 319
- CAGR *see* compound annual growth rate
- cancer 336, 346, 352
- cancer cells 29
- Carbon Nanotechnologies, Inc. 178
- carbon nanotube (CNT) 2–3, 24–27, 36–37, 45–46, 54–55, 62, 148–52, 166–68, 177–78, 180, 187, 192, 199, 243, 254–55, 258, 261, 275, 333, 354, 362–63, 401–3
- carbon nanotubes, grades of 177–78
- carcinogen 346, 352, 370–71
- case study commercialisation
challenges 223, 225
- caveolin-mediated endocytosis 339
- cell cycle 340, 342
- cell death 342, 346, 348
- cellular response 346
- cellular uptake 332–33, 337–38, 341, 353, 363
- certified reference materials (CRMs) 295, 307, 324
- change agents 292, 424–26
- chemical composition 334, 338, 342
- chemical mechanical planarisation (CMP) 55
- chemical mechanical planarisation slurry 43, 55, 140
- chemical reactivity 334
- chemical vapour deposition (CVD) 149–50
- chitosan 363
- civil society groups 411, 415
- clastogenic 349
- clathrin-mediated endocytosis 339
- clean energy technology 44, 47
- clearance 335–37, 342, 346
- clinical trials 53, 194, 206
- CMAR (carcinogen/mutagen/asthmagen/reprotox) 370
- CMP *see* chemical mechanical planarisation
- CNT *see* carbon nanotube
- CNT products 152, 256
- co-citation analysis 240
- CO oxidation 82, 85, 125, 130, 132–33
- co-regulation 270–71
- coercivity 28–30
- cohesive energy 6–7
- collaborative research 261–62
- commercialisation 171–202, 261
- common exposure scenarios 394–95
- community engagement 409, 415–16, 423, 426–27, 438, 442
- company valuation 197

- compound annual growth rate (CAGR) 41, 49, 51, 53–54
 conceptualising nanowaste 382–83, 385
 consumer electronics 210, 222, 224, 226, 230, 232–33
 containment 356, 364, 369
 contaminant 341, 343, 359
 contamination 143, 146, 359
 continuous hydrothermal synthesis 101, 127
 control banding 355, 368–71, 373–74
 control banding nanotool 370
 copper 25, 108, 148, 349
 coprecipitation 77–78, 106
 cosmetic 336
 critical path methodology 392
 CRMs *see* certified reference materials
 cryptic epitopes 345
 crystal structures 9–13, 28, 33, 89, 109, 111, 334
 metastable 9–10
 crystalline silica 352
 cytosol 338
 cytotoxicity 341–42, 343, 346, 348–51, 353, 362
 CVD *see* chemical vapour deposition
 cytokines 344–46
 cytotoxicity 342–43, 346, 349–51, 353, 362

 DCS *see* differential centrifugal sedimentation
 DEEPEN *see* Deepening
 Ethical Engagement and Participation in Emerging Nanotechnologies
 Deepening Ethical Engagement and Participation in Emerging Nanotechnologies (DEEPEN) 437
 deficit model 413–14
 DEG *see* diethylene glycol
 dendrimers 49–50, 354
 deposition-precipitation 74, 81, 83
 homogeneous 83
 dermal absorption 347
 dermal exposure 335–336, 351, 366, 368
 dermal protection 367
 diethylene glycol (DEG) 108–9
 differential centrifugal sedimentation (DCS) 295, 298, 317–20, 324
 differentiators 202
 dispersion 289, 300–1
 disposal of product 356
 distribution 334–35, 337, 340
 DLS *see* dynamic light scattering
 DNA damage 334, 348–49
 dopants 343, 348
 dose response characterisation 358
 dosimetry 360
 downstream user responsibility 392
 drug delivery 24, 50–52, 60
 dynamic light scattering (DLS) 18, 155, 199, 295–96, 298, 300, 302–4, 320, 322, 324, 326, 328, 330

 economic logic 202
 electron microscopy (EM) 290, 322, 325
 electrostatic precipitation 365
 elimination 337, 360–61
 EM *see* electron microscopy
 encapsulation 351, 362–63
 enclosure 361, 364–66, 368, 371
 endocytosis 338–39, 363

- endosomes 338, 340–41, 349, 353
- energy nanotechnology 47, 49
- energy saving technology 49
- energy storage 45–46, 48
- energy usage 46, 53
- engineering controls 360–61, 365–68, 371
- environmental fate 352, 354
- environmental monitoring 372
- epidermis 336
- European Commission Joint Research Centre 354
- European Parliament 266, 274–75, 279
- excretion 335, 337, 353
- experiential marketing 184, 188–89
- explosivity 366
- exposure assessment 345, 358–60
- exposure monitoring 359–360
- exposure standard 352, 355, 357
- extended producer responsibility 395
- eye protection 368

- face masks 367
- FDA *see* Food and Drug Administration
- Fenton chemistry 343
- ferrimagnetic materials 27–28
- ferromagnetic materials 28
- FFF *see* field flow fractionation
- FFFF *see* flow field-flow fractionation
- fibre-like 332, 334, 342, 362
- fibrogenic agents 343
- field flow fractionation (FFF) 298, 320–22, 325
- FIPCO 193
- flame spray pyrolysis (FSP) 33, 74, 110–11, 113, 127–28, 135
- flammability 366, 371
- flow field-flow fractionation (FFFF) 320, 322, 325
- Food and Drug Administration (FDA) 194–95
- free radicals 334, 350
- FSP *see* flame spray pyrolysis
- fuel cells 44–45, 49, 215, 224, 230
- fullerene production 151, 167, 400
- fullerenes 3, 24, 32, 49–50, 139, 148, 150–53, 165, 168, 277, 333, 337, 341, 354, 362–63, 401
- fully integrated pharmaceutical company 193
- fume hoods 365
- fumed silica 352, 357

- genotoxicity 335, 342, 347, 349
- glove material 368
- GM food debate 407
- GM foods 407, 415, 429, 441, 443
- gold 65, 76, 82, 84, 109, 126–27, 130, 134, 139, 147–48, 295–96, 310, 336, 354
- gold particles 76, 315
- granulomatous lesions 351
- graphenes 2–3, 24, 26–27, 33–34, 45
- growth curve 255–58

- hazard 332–33, 337, 346, 352, 355–58, 361–62, 366, 368–69, 372–73
- hazard identification 358
- HEPA filters 365, 367
- hierarchy of controls 355, 360–61
- high efficiency particulate air (HEPA) filtration 365

- hydrodynamic diameter 337, 342, 353
- hydrolysis 85–87
- hydrophilicity 341, 362–63
- hydrothermal synthesis 74, 80, 98–104, 126, 131, 134, 137
- Hyperion 207–11, 224, 226–28, 231, 233
- Hyperion catalysis 207–8, 223, 231, 235
- hypersensitivity

- IARC *see* International Agency for Research on Cancer
- ICON *see* International Council on Nanotechnology
- immortalized cells
- immune response 335–36
- immune system 339, 342, 344–45
- immunostimulation 344
- immunosuppression 344
- immunotoxic potential 343–44
- incineration 356, 367, 388, 398
- incineration of regulated wastes 398
- industries
 - automotive 39, 63–64, 69, 209
 - biotechnology 177, 193–94
 - chemical 269, 283, 285
 - electronic 73–74
 - information technology 41, 190
 - nano-related 355–56
 - textile 66
- inflammation 336, 342, 344, 346–47, 351
- inflammatory responses 344
- inhalation 335, 346, 369
- inhalation studies 333, 336, 347, 351
- insolubility 334
- International Council on Nanotechnology (ICON) 333
- International Patent Classification 240
- intratracheal inhalation 347
- intratracheal instillation 336
- intravenous 347, 353
- ionic-liquid assisted methods 74
- ionic liquids 118–19, 126, 132, 135
- institutional theory 175
- intellectual property strategy 258
- interactive market engagement 184, 193
- International Agency for Research on Cancer (IARC) 346–47, 352
- International Organization for Standardization 262, 290–92, 325
- International System of Units (SI) 289, 326
- investors 179, 190, 196–97, 201
- iron 343, 349, 354
- ISO 26000 395

- Japan Patent Office 241

- knowledge gap, applications 180, 182–83

- Langerhans cells 339
- laser diffraction 299, 304–6, 325
- LCA *see* lifecycle assessments
- LCA parameters 382, 387
- lead 353
- lead user 184–85, 190, 197, 200
- legislation 266–67, 269–70, 272, 274

- LEV *see* local exhaust ventilation
- life cycle assessments (LCA) 382, 386–87, 39
- life cycle of manufacture 361
- liquid-phase methods 157–59
- liquid-phase technique 144–45, 148
- liquid suspensions 383
- liver 336–37, 341, 347, 351
- liver sinusoids 337
- local exhaust ventilation (LEV) 364
- lung fibrosis 336
- lungs 336–37, 346–47, 351
- lysosomes 340, 353
-
- macrophages 336, 339–40, 342, 344, 375
- macropinocytosis 339
- magnetic materials 27, 29–30
- magnetisation 27–31
- MALS *see* multi-angle light scattering
- mammalian toxicology 354
- mass and energy balance analysis 393
- material safety 354, 357
- material safety data sheets 357
- maximum penetrating particle size (MPPS) 365
- measurand 288–89, 299–300, 302, 305, 307, 309, 317, 323
- measurement 287–90, 292, 295, 297–312, 314, 316–20, 322–24
- measurement techniques 298–99
- mechano-chemical processing 74, 116–18
- mesothelioma 342
- metabolism 335, 337
- metal oxides 74, 77, 81–82, 89, 113, 126, 131, 142, 144, 147
- metal precursors 84–85, 87, 89, 92, 113
- metals 2, 5, 8, 22, 74, 81–82, 85, 109, 113, 127, 129, 133, 147, 296, 349–50
- metrology 288–90, 297, 323
- micelles 76, 92, 143
- microemulsion techniques 74, 92–93, 95, 97
- microemulsions 74, 92–98, 121, 126, 130, 133, 137, 359
- microwave-assisted techniques 74, 104–6
- microwave irradiation 105, 107, 137
- mitochondrial disruption 343, 346
- mixed oxides 77–78, 91, 106, 115, 126–27, 131–32
- modification options 350, 362, 364
- monitoring and targeting analysis 393
- MPPS *see* maximum penetrating particle size
- multi-angle light scattering (MALS) 300, 320, 322
- multi-disciplinarity 240
- multi-walled carbon nanotubes (MWCNTs) 25, 150, 207–8, 293, 354
- MWCNTs *see* multi-walled carbon nanotubes
-
- nano cafes 439
- nano ceria 348, 362
- nano clays 354
- nano-enabled commercial products 1, 32, 67, 139
- nano gold 350–51

- nano silica 342, 352, 362
- nano silver 334, 337, 351–52, 363, 365, 386
- nano TiO₂ 346–49
- nano ZnO 348–50
- nanocapsules 49, 60
- nanocomposites 15, 17–19, 47, 113
- nanofabrication 100, 387
- nanofibres 45, 49–50, 58–59, 294, 328
- NANOhub 354
- Nanojury 411, 431, 436
- nanolabelling 357
- nanomaterials
 - carbon-based 2, 24
 - disposal of 356, 359, 361, 367–69, 371, 373
 - engineered 59, 266, 294, 331, 337, 346, 355, 361–62, 364, 366–70, 372, 374–75, 378, 383, 401–2
 - fibrous 370
 - filtration of 364–65, 371
 - handling of 333, 342, 357, 360–61, 366, 368–73
 - incidental 383, 385
 - nanomaterials, incidental 383, 385
 - regulation of 199, 202, 273, 357
 - soluble 370
- nanometric debris 383
- nanometrology 288, 290
- nanoparticle additives 62
- nanoparticle catalysts 47, 136, 151–52
- nanoparticle characterisation 2, 301, 354
- nanoparticle dispersion systems 14–15
- nanoparticle emission assessment technique (NEAT) 360
- nanoparticle metrology 297
- nanoparticle of concern 334, 356
- nanoparticle properties 297
- nanoparticle size measurements 299, 302–03, 305, 307, 309, 311, 313, 315, 317, 319, 321
- nanoparticle uptake by cells 337–38
- nanoparticles
 - carbon 113, 336
 - carbonaceous 341–42, 362–63
 - CeO₂ 56, 80, 154, 164
 - ceramic 3, 37, 45
 - commercial 145, 154–55, 157, 159, 161, 163
 - commercial-scale production of 139–41, 143–54, 156, 158, 160, 162, 164, 166, 168
 - diamond 148, 153
 - engineered 287, 325, 332, 337, 378
 - gold 7, 22, 33–35, 40, 84, 134, 137, 294, 350
 - handling of 17–18
 - inorganic 74, 123, 142, 146
 - magnetic 27, 29–30, 32–34, 50, 56, 67
 - metal 22, 34–35, 45, 56, 75, 129, 131, 293
 - metal oxide 12, 62, 124, 126, 129–30, 134, 145, 147, 347, 349, 362
 - semiconductor 8, 12, 20
 - silver 22–23, 49–50, 54, 56, 65, 134, 137, 402
 - SiO₂ 45, 62
 - TiO₂ 11, 45, 60, 62, 87, 128, 133
 - ZnO 17, 50, 134–35, 154–56, 158–59, 169, 349, 375–76
 - ZrO₂ 10–11
- nanoparticulates 344, 365
 - monitoring of 387

- nanopollution 383
- nanoporous membranes 399
- nanopowders 76–78, 87, 104, 115, 127, 366
- nanoproduct lifecycle 388–89
- nanorods 93, 96, 99–100, 125, 138
- nanosafety 331–33, 353–54, 358, 372
- nanoscale 288, 291–92, 295, 311, 323
- nanosensors 399
- nanospheres 352–53
- nanotechnology commercialisation diamond 201
- Nanotechnology Engagement Group 436
- nanotechnology IP 182
- nanotechnology value chain 43, 291
- nanotoxicology 331–54
- nanovector 340, 343–44
- nanowaste 356, 373, 381–99, 403
 - collection of 397
 - nanowaste containment 398
 - nanowaste generation 390–91
 - nanowaste management 356, 381–82, 389–90, 392, 394, 399
 - nanowaste management policy principles 390
 - nanowaste management protocols 394
 - nanowaste measurement parameters 390
 - nanowaste practices 388
 - nanowaste risk assessment 393
 - nanowaste risk management 392–93, 395
 - nanowaste spill kits 397
 - nanowires 352–53
- National Enabling Technologies Strategy 441
- National Nanotechnology Initiative 239
- NEAT *see* nanoparticle emission assessment technique
- necrosis 342
- neurotoxic potential 343
- NGOs 408–9, 415, 417–19, 424, 426, 436
- nomenclature 287
- occupational and environmental health and safety 199, 201
- occupational exposure limits (OEL) 357
- occupational health and safety 332, 355–73
- OEL *see* occupational exposure limits
- off-shoring pollution 395
- oil-in-water 92
- olfactory bulb 336, 343
- open innovation 175, 184
- oral exposure 351
- organic solvents 77, 85–86, 88–89, 97, 118, 122, 145
- Organisation for Economic Co-operation and Development (OECD) 333, 353–54, 358, 361
- oxidative stress 334, 341, 343, 346–48
- paramagnetic materials 27, 30
- particle agglomeration 17, 120, 145, 161
- particle characterization 292
- particle overload phenomenon 347

- particle shape 341–42, 351–52
- particle size 334, 337–38, 341, 347, 362, 364, 366
- particle size distribution (PSD) 8, 18, 81, 157, 302–5, 307, 309, 315–16, 319, 322–23, 325, 327, 334, 360
- particle tracking analysis (PTA) 298, 300, 314–17, 325, 435
- particokinetics 360
- patent application 178, 240–43, 245–59, 261, 263
 - trend in 242–43, 245, 247, 249, 251, 253, 255
- patents 207–11, 225–26, 233, 242, 246–48, 255, 261–64
- pathogens 54, 58, 60
- penetrance 334, 336, 341
- peroxisomes 353
- personal care products 39, 66–67, 348
- personal protective equipment 360–61, 364–68, 383, 397
- phagocytosis 338–39
- phagosomes 340
- photoactivity 334, 350
- photoactivity rate constant 159–60, 163
- photobleaching 347
- photocatalysis 45, 132, 158–59, 164, 166, 348, 350
- photogenotoxicity 334
- phototoxic 340, 347
- physicochemical properties 334, 356
- pinocytosis 339
- platform technology 176, 180
- polarity 341
- polluter pays principle 392
- polyethylene glycol 341, 363
- polyol methods 74, 107–9
- polystyrene 113, 295–96, 316, 362
- polystyrene latex 295–96, 325
- porosity 334
- potential hazards 333, 362
- precautionary principle 355
- precipitation 74, 77, 79–80, 84, 101, 359, 365
- product development 171–76, 182, 187–91, 193–98, 200–1
- production scale-up 139–41, 171, 179, 198, 226
- protein corona 338–40, 345
- proteins 29, 242, 338–41, 345
- PSD *see* particle size distribution
- PTA *see* particle tracking analysis
- public attitudes 408–9, 429
- public debates 409, 426, 434, 438, 443
- public engagement 280, 405–445
- public participation 416, 425, 427, 446
- pulmonary particle overload 336
- QDs *see* quantum dots
- quality control in the whole product 199, 201
- quantitative (surface) structure activity relationship 358
- quantum dots (QDs) 20–21, 45, 49–50, 55, 144, 147, 353, 362–63, 374
- reactive grinding 359
- reactive oxygen species (ROS) 298, 334, 343–44, 346
- recycling 356, 367–68
- reducing agent 87, 89, 97, 99, 108, 121

- reference materials 287–88, 292, 295, 304, 307, 309, 314, 317, 319–20, 323, 325–26
- regulatory effectiveness 266, 270–75
- regulatory models 267
- respirator 365, 367
- respiratory protective equipment (RPE) 367
- risk assessment 333, 346, 356, 358, 366, 369, 371, 375, 389, 434
- risk characterisation 358
- risk management 345, 358, 361, 365, 368–69, 370–71
- ROS *see* reactive oxygen species
- RPE *see* respiratory protective equipment
- rutile 347–48, 362

- safe handling 333, 369, 372
- safety-by-design approaches 332–33, 346, 355
- safety data sheets 357, 392
- sampling 287, 300–1, 309
- saturation magnetisation 28–31
- SAXS *see* small angle X-ray scattering
- scanning electron microscopy (SEM) 76, 79, 102, 295–96, 298, 309–11, 326
- science-based businesses 205–6, 235, 237
- scoping audit 393
- SDS *see* sodium dodecyl sulphonate
- sedimentation field-flow fractionation (SFFF) 320, 322, 326
- selenium 353
- self-contained breathing apparatus 368, 371
- self-regulation 269–70
- SEM *see* scanning electron microscopy
- semiconductor materials 20–22
- serum protein binding 341
- SFFF *see* sedimentation field-flow fractionation
- SI *see* International System of Units
- silicosis 352
- silver nanoparticle coating 60
- single-walled carbon nanotubes (SWCNTs) 25–26, 148, 150–51, 169, 293, 354
- skin 50, 339, 347–49
- skin penetration 336
- small angle X-ray scattering (SAXS) 296–97, 300, 306–7, 325
- social inclusion 409, 423–24, 427
- social responsibility 382, 395
- sodium dodecyl sulphonate (SDS) 81, 357, 392–93
- soft law 269
- sol-gel method 74, 85–89, 91, 122
 - aqueous 86–87
- solar cells 22, 24, 44–45, 55–56, 211, 215–17, 224
- solid matrices 383
- solid-phase technique 73, 142, 145–46
- solvothermal methods 74, 98–99, 101–4, 122
- specification tolerance in the whole product 199
- spiral product development
 - methodology 176, 187–88, 190, 193, 196–98, 200, 230
- SPR *see* surface plasmon resonance
- spray pyrolysis 74, 110–11, 113
- stage-gate new product development 191
- staging 202
- standardization 262

- sunscreens 14, 17, 43, 66–67, 140, 159, 333, 347, 349–50, 374–75, 386
 superparamagnetic materials 30
 surface area 334, 341, 347, 350, 360
 surface charge 334, 337–38
 surface chemistry 334, 341
 surface coatings 351, 353, 363
 surface defect luminescence 12
 surface plasmon resonance (SPR) 40, 299, 326
 surface plasmons 22, 35
 surfactants 81, 92, 94, 97, 119, 143, 297, 301
 suspendants 301, 303, 305, 316, 318, 322
 SWCNTs *see* single-walled carbon nanotubes
 synchronised systems 395
 system decomposition 394
- target cell 341–42
 technology assessment 440
 technology licensing organisations (TLOs) 262
 technology readiness level 193
 TEG *see* tetraethylene glycol
 TEM *see* transmission electron microscopy
 template-directed synthetic techniques 74, 113, 115
 teratogenic 352
 tetraethylene glycol (TEG) 108
 textiles 3, 39, 41, 53, 58–59, 266, 400
 tissue distribution 334
 titanium dioxide 333, 354, 362, 386
 TLOs *see* technology licensing organisations
- toluene 102–4
 top-down production 359
 toxic metal 353
 toxic potential 333, 343–44, 351–53, 372
 toxicity 26, 35, 152, 202, 334–35, 342–44, 347, 350–53, 363, 378, 402
 toxicokinetic 335
 traceability 289–90, 295
 transdermal penetrance 336
 translocation 343
 transmission electron microscopy (TEM) 76, 79, 81, 84, 93–95, 102, 155–56, 162, 199, 293, 295–96, 298, 307–11, 326
 true cost waste assessment 393
 tumour cells 30, 50
- ultrafine dusts 371
 ultrafine particles 357
 ultrafine TiO₂ particulates 370
 ultraviolet light 334
 uncertainty 289, 324
 Unidym 177–79, 187, 192–93
 United States Patent and Trademark Office 240
 UV screening applications 11
- valley of death 171–75, 181, 191, 196, 198, 202–3, 220
 valuation milestone 196
 vapour-phase methods 148, 156–59
 vapour phase reactions 359
 vehicle 202
 ventilation 361, 369, 371
 venture capital 193, 196–98

- WASOP *see* Waste and Source Material Operability Study
- Waste and Source Material Operability Study (WASOP) 394
- waste assessment principles 393
- waste disposal 367, 373
- waste haven effect 399
- water-in-oil 92, 94–95
- water-in-supercritical CO₂ 92
- Web 2.0 442–43
- whole of life-cycle analysis 332, 355
- Wisepower Co., Ltd 178
- work health and safety assessment 370
- work practices 367
- Working Party on Manufactured Nanomaterials (WPMN) 353
- workplace controls 332, 345, 355, 357, 359–61, 363, 365–67, 369, 371–73, 375
- workplace monitoring 359–60
- World Intellectual Property Organization 242
- zinc 349–50
- zinc oxide 333, 348, 354, 362